Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability

Dec 17, 2021 | Press Releases

Quantification of the structure and composition of the vessel wall and assessment of lipid-rich necrotic core plaque (CPT 0710T-0713T) BOSTON – December 17, 2021 – Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial...

Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes

Oct 29, 2021 | Press Releases

ACC/AHA Endorse Cardiovascular Computed Tomography Angiography (CCTA) in New Chest Pain Guidelines BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued...

Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Jul 16, 2021 | In the News

Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected...

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

Apr 17, 2021 | In the News

Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or...

Study Demonstrates Elucid’s Ability to Estimate RNA Expression from Non-Invasive Cardiovascular Imaging

Mar 22, 2021 | In the News

Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable...